Business Practice

Why cell and gene therapy manufacturing has a lot to learn from the automotive sector.

Delali Attipoe at the DNDi explains why we need an R&D model attuned to the needs of forgotten patients.

The public’s perception of the industry is low. How can we fix it?

Experts from Lonza share how biologics and CGT can recognize the gaps and similarities that can be utilized to optimize cell culture media challenges.

The Alliance for RTU has been founded to accelerate and improve manufacturing quality, consistency, and regulatory efficiency.

Why the traditional model of drug development is no longer fit for purpose.

Sitting Down With… Lars Petersen, President and CEO, FUJIFILM Diosynth Biotechnologies

Biopharma companies procrastinating on sustainability measures risk falling behind, according to Cytiva’ Global Biopharma Sustainability Review.

Civica Rx is approaching generic drug manufacturing using a nonprofit model – and it’s working. We get the story behind their facility in Petersburg.

With open minds and open sources, the future is foundational – and bright.